AUPH News and Press, Aurinia Pharmaceuticals Inc From 07/26/21

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its second quarter 2021 financial results on Thursday, August 5, 2021, after the markets close. Aurinia’s management team will also host a conference call at ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company), a commercial stage biopharmaceutical company advancing therapies for severe autoimmune diseases, announced today it will voluntarily delist the common shares of the Company from the Toronto Stock Exchan...

Investors continue to be hungry for growth after the insane amount we saw in 2020 from TSX stocks. After a huge crash and a pandemic to boot, Canadians learned to save — a lot . In fact, analysts have stated that, on average, Canadians saved more in the last year than they ha...

When it comes to finding cheap TSX stocks there are a few things you need to take into consideration, but not necessarily all at once. There might be a cheap share price you want to consider. There could be a future growth opportunity that makes it a discount. Or there could be a pullba...

Earnings season is upon us yet again, and investors are hungry for stocks that could soar. After a year of growth stocks in 2020, investors across the world are greedy for more stocks that could double in a short period. Now here at the Motley Fool, we don’t recommend buying a st...

Investors are always looking for a deal, but it’s getting harder to find. There’s an oil and gas rebound, the pandemic is coming to a close, and economies around the world continue to reopen. The TSX continues to trade at all-time highs, up 250 points in the last month alo...

The TSX continues to climb past record highs this month, passing the 20,000-point mark and not looking back. As the economy continues to recover during the pandemic for a post-pandemic world, there are a few industries that investors should consider. There are still many undervalued sto...

Five patient organizations will receive funds to implement plans aimed at reducing health disparities, connecting people living with systemic lupus erythematosus (SLE) and lupus nephritis (LN) with needed health management resources Aurinia Pharmaceuticals Inc. (NASDAQ: ...

Aurinia Pharmaceuticals' (AUPH) licensing partner, Otsuka Pharmaceutical ((OPEL)) has filed an initial Marketing Authorization Application ((MAA)) for voclosporin for the treatment of lupus nephritis ((LN)) to the EMA.LN is a complication of the autoimmune disease systemic lupus erythematosus...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) announced today that the Company’s licensing partner, Otsuka Pharmaceutical Europe Ltd. (OPEL), filed an initial Marketing Authorization Application (MAA) for voclosporin for the treatment of lupus nephritis...